{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T21:42:52Z","timestamp":1773351772783,"version":"3.50.1"},"reference-count":57,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Eosinophilic esophagitis (EoE) is an inflammatory condition of the esophagus that is quickly becoming a more recognized cause of esophageal dysfunction and dysphagia. The cause of EoE is thought to be due to an inflammatory response triggered by exposure to dietary or environmental antigens. Symptoms may be progressive and include reflux, nausea, vomiting, dysphagia, and reduction in quality of life. Both children and adults may be affected. Initial treatments for EoE have focused on elimination diets to potentially identify and remove dietary triggers, acid suppression with proton pump inhibitors, and topical delivery of orally administered swallowed corticosteroids. These therapies are often ineffective in a large proportion of patients, leading to exploration of other approaches by focusing on cytokines involved in the inflammatory response. Most recently, dupilumab, a monoclonal antibody targeting IL\u20104 received approval for use in patients aged 12\u2009years or older with EoE. Use of dupilumab has seen favorable improvements in disease progression and symptoms with chronic use. Other therapies targeting IL\u20105, such as mepolizumab, reslizumab, and benralizumab are currently being studied for use in EoE. Therapies targeting other key inflammatory mediators in EoE, such as Siglec\u20108 (lirentelimab), IL\u201013 (cendakimab), and the sphingosine 1\u2010phosphate receptor (etrasimod) are currently being evaluated in clinical trials.<\/jats:p>","DOI":"10.1002\/phar.2783","type":"journal-article","created":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T08:19:41Z","timestamp":1677313181000},"page":"338-348","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Emerging therapies for eosinophilic esophagitis"],"prefix":"10.1002","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0491-4187","authenticated-orcid":false,"given":"Patrick D.","family":"Meek","sequence":"first","affiliation":[{"name":"Albany College of Pharmacy and Health Sciences  Albany New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0995-6124","authenticated-orcid":false,"given":"Brian","family":"Hemstreet","sequence":"additional","affiliation":[{"name":"University of Colorado Department of Clinical Pharmacy  Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2021.08.001"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2014.02.002"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.09.008"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.06.023"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.06.067"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14072"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-052819-023848"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v6.i4.150"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/dote\/dox050"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.giec.2007.09.009"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.09.052"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/dote\/doy015"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.11.011"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14112"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.02.038"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.14920"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-021-00855-y"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.10.027"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756284820980860"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.04.022"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.06.020"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.08.050"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2032506"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.821871"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-014-8444-9"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00691-x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.09.042"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.08.383"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2022.01.019"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2205982"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reval.2022.02.199"},{"key":"e_1_2_7_33_1","unstructured":"Dupixent\u00ae [Package Insert].2017Tarrytown New York Regeneron Pharmaceuticals. Accessed December 13 2022.https:\/\/www.regeneron.com\/downloads\/dupixent_ppi.pdf"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.798"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.08.051"},{"key":"e_1_2_7_36_1","unstructured":"Dupixent\u00ae (dupilumab SOL 300 mg\/2 ml SC 2 ml 2\u2009s) [NDC 00024\u20135915\u201002].2023Micromedex RedBook [database on the Internet]. Greenwood Village (CO): IBM Corporation. Accessed February 17 2023. Subscription required to view. [Accessed February 14 2023].http:\/\/www.micromedexsolutions.com"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.09.007"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.02.033"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.178558"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.07.044"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.02.042"},{"key":"e_1_2_7_42_1","unstructured":"A multi\u2010center randomized double\u2010blind parallel\u2010arm placebo\u2010controlled trial of mepolizumab for treatment of adults and adolescents with active eosinophilic esophagitis and dysphagia\u2010predominant symptoms. ClinicalTrials.gov. Bethesda MD: National Library of Medicine (US). 2018 Identifier NCT03656380.2022Nov 30; [about 11 screens]. Accessed December 13 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03656380"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.11.044"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001840"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i14.4502"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003319"},{"key":"e_1_2_7_47_1","unstructured":"ClinicalTrials.gov. Bethesda MD: National Library of Medicine (US).2020Identifier NCT04543409 A Multicenter Randomized Double\u2010Blind Parallel\u2010Group Placebo\u2010Controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis (MESSINA); 2020 Sep 10; [about 10 screens]. Accessed December 13 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04543409"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012047"},{"key":"e_1_2_7_49_1","unstructured":"ClinicalTrials.gov. Bethesda MD: National Library of Medicine (US).2020Identifier NCT04322708 A Phase 2\/3 Multicenter Randomized Double\u2010Blind Placebo\u2010Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab (AK002) in Adult and Adolescent Patients with Active Eosinophilic Esophagitis; 2021 Jul 30; [about 10 screens]. Accessed December 14 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04322708"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.10.051"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.03.036"},{"key":"e_1_2_7_52_1","unstructured":"ClinicalTrials.gov. Bethesda MD: National Library of Medicine (US).2021Identifier NCT04991935 A Phase 3 Multicenter Multinational Open\u2010Label Extension Study to Evaluate the Long\u2010Term Safety of CC\u201093538 in Adult and Adolescent Subjects with Eosinophilic Esophagitis; 2022 Dec 13; [about 6 screens]. Accessed December 12 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04991935"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.10.035"},{"key":"e_1_2_7_54_1","unstructured":"ClinicalTrials.gov. Bethesda MD: National Library of Medicine (US).2020Identifier NCT04682639 A Phase 2 Randomized Double\u2010Blind Placebo\u2010Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects with Eosinophilic Esophagitis; 2022 Dec 12; [about 6 screens]. Accessed December 12 2022https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04682639"},{"key":"e_1_2_7_55_1","unstructured":"Tezspire\u00ae [Package Insert] Amgen. Accessed February 17 2023.https:\/\/www.tezspire.com\/"},{"key":"e_1_2_7_56_1","unstructured":"ClinicalTrials.gov. Bethesda MD: National Library of Medicine (US).2022Identifier NCT05583227 A Randomized Double\u2010Blind Parallel\u2010Group Placebo\u2010Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING); 2022 Oct 17; [about 5 screens]. Accessed February 10 2023.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05583227"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113483"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.05.036"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2783","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2783","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2783","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:05:56Z","timestamp":1761048356000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1002\/phar.2783"],"URL":"https:\/\/doi.org\/10.1002\/phar.2783","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"2022-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}